Consequently, SHBG serves as a sensitive biomarker of metabolic-endocrine status, further refining clinicians’ and research scientists’ ability to detect subclinical hyperinsulinaemia (SCHI) and, therefore, the associated increased risk for certain cancers, cardiovascular and neurodegenerative diseases. The gene discussed is SHBG; the disease is cancer.